Joint arthrodesis utilizing autogenous bone graft remains the gold standard of treatment in fusion procedures of the foot and ankle. Graft harvest, however, has been associated with increased morbidity to patients as well as increased costs. With this in mind, multiple clinical studies have evaluated the efficacy of recombinant human platelet-derived growth factor (rh-PDGF-BB) with beta-tricalcium phosphate (B-TCP) to augment in foot and ankle arthrodesis with favorable results. These factors have led to the increased use of rh-PDGF-BB with B-TCP in Vancouver with good clinical results.
Keywords: Bone graft substitute; Foot and ankle arthrodesis; Fusion; PDGF, Platelet-derived growth factor; Recombinant human platelet-derived growth factor.
Copyright © 2016 Elsevier Inc. All rights reserved.